Medical Coverage Policy | Transcatheter Mitral Valve Repair

EFFECTIVE DATE: 04|01|2020
POLICY LAST UPDATED: 09/21|2022

OVERVIEW

Transcatheter mitral valve repair (TMVR) is an alternative to surgical therapy for mitral regurgitation (MR). MR is a common valvular heart disease that can result from a primary structural abnormality of the mitral valve (MV) complex or a secondary dilation of an anatomically normal MV due to a dilated left ventricle caused by ischemic or dilated cardiomyopathy. Surgical therapy may be underutilized, particularly in patients with multiple comorbidities, suggesting that there is an unmet need for less invasive procedures for MV repair. One device, MitraClip, has approval from the U.S. Food and Drug Administration for the treatment of severe symptomatic MR due to a primary abnormality of the MV (primary MR) in patients considered at prohibitive risk for surgery and for patients with heart failure and moderate-to-severe or severe symptomatic secondary MR despite the use of maximally tolerated guideline-directed medical therapy.

MEDICAL CRITERIA

Medicare Advantage Plans
See Coding section.

Commercial Products
Primary Mitral Valve Regurgitation
Transcatheter mitral valve repair with a device approved by the U.S. Food and Drug Administration for use in mitral valve repair may be considered medically necessary for patients with symptomatic, primary mitral regurgitation who are considered at prohibitive risk for open surgery.

Definition:
* Prohibitive risk for open surgery may be determined based on:

- Presence of a Society for Thoracic Surgeons predicted mortality risk of 12% or greater and/or
- Presence of a logistic EuroSCORE of 20% or greater.

Heart Failure and Secondary Mitral Valve Regurgitation
Transcatheter mitral valve repair with a device approved by the U.S. Food and Drug Administration may be considered medically necessary for patients with heart failure and moderate-to-severe or severe symptomatic secondary mitral regurgitation despite the use of maximally tolerated guideline-directed medical therapy.

Definitions:
*Moderate to severe or severe MR may be determined by:

- Grade 3+ (moderate) or 4+ (severe) MR confirmed by echocardiography
- New York Heart Association (NYHA) functional class II, III, or IVa (ambulatory) despite the use of stable maximal doses of guideline-directed medical therapy and cardiac resynchronization therapy (if appropriate) administered in accordance with guidelines of professional societies.

*Optimal medical therapy may be determined by guidelines from specialty societies such as:

- American Heart Association/American College of Cardiology Guideline for the Management of Patients with Valvular Heart Disease

- European Society of Cardiology/European Association for Cardio-Thoracic Surgery Guidelines for the Management of Valvular Heart Disease
- American Heart Association/American College of Cardiology/Heart Failure Society of America Guideline for the Management of Heart Failure

PRIOR AUTHORIZATION

Medicare Advantage Plans
See Coding section.

Commercial Products
Prior authorization is recommended for Commercial Products.

POLICY STATEMENT

Medicare Advantage Plans
Transcatheter mitral valve repair with a device approved by the U.S. Food and Drug Administration (FDA) may be considered medically necessary for patients enrolled in a Centers for Medicare and Medicaid Services (CMS) approved clinical trial. Refer to Related Policy section.

Note: Blue Cross & Blue Shield of Rhode Island (BCBSRI) must follow Centers for Medicare and Medicaid Services (CMS) guidelines, such as national coverage determinations or local coverage determinations for all Medicare Advantage Plan policies. Therefore, Medicare Advantage Plan policies may differ from Commercial products. In some instances, benefits for Medicare Advantage Plans may be greater than what is allowed by the CMS.

Commercial Products
Transcatheter mitral valve repair with a device approved by the U.S. Food and Drug Administration may be considered medically necessary when the medical criteria above has been met, and is not medically necessary in all other situations, as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable surgery benefits/coverage.

BACKGROUND

MITRAL REGURGITATION

Epidemiology and Classification
Mitral regurgitation (MR) is the second most common valvular heart disease, occurring in 7% of people older than age 75 years and accounting for 24% of all patients with valvular heart disease. MR with accompanying valvular incompetence leads to left ventricular (LV) volume overload with secondary ventricular remodeling, myocardial dysfunction, and left heart failure. Clinical signs and symptoms of dyspnea and orthopnea may also be present in patients with valvular dysfunction.~~3,~~ MR severity is classified as mild, moderate, or severe disease on the basis of echocardiographic and/or angiographic findings (1+, 2+, and 3-4+ angiographic grade, respectively).

Patients with MR generally fall into 2 categories: primary (also called degenerative) and secondary (also called functional) MR. Primary MR results from a primary structural abnormality in the valve, which causes it to leak. This leak may result from a floppy leaflet (called prolapse) or a ruptured cord that caused the leaflet to detach partially (called flail). Because the primary cause is a structural abnormality, most cases of primary MR are surgically corrected. Secondary MR results from left ventricular dilatation due to ischemic or dilated cardiomyopathy. This causes the mitral value (MV) leaflets not to coapt or meet in the center. Because the valves are structurally normal in secondary MR, correcting the dilated left ventricul~~ar~~ using medical therapy is the primary treatment strategy used in the United States.

Standard Management

Surgical Management

In symptomatic patients with primary MR, surgery is the main therapy. In most cases, MV repair is preferred over replacement, as long as the valve is suitable for repair and personnel with appropriate surgical expertise are available. The American College of Cardiology and the American Heart Association have issued joint guidelines for the surgical management of MV.

The use of standard open MV repair is limited by the requirement for thoracotomy and cardiopulmonary bypass, which may not be tolerated by elderly or debilitated patients due to their underlying cardiac disease or other conditions. In a single-center evaluation of 5737 patients with severe MR in the United States, Goel et al (2014) found that 53% of patients did not have MV surgery performed, suggesting an unmet need for such patients.

Isolated MV surgery (repair or replacement) for severe chronic secondary MR is not generally recommended because there is no proven mortality reduction and an uncertain durable effect on symptoms. Recommendations from major societies regarding MV surgery in conjunction with coronary artery bypass graft surgery or surgical aortic valve replacement are weak because the current evidence is inconsistent on whether MV surgery produces a clinical benefit.

Transcatheter MV Repair

Transcatheter approaches have been investigated to address the unmet need for less invasive MV repair, particularly among inoperable patients who face prohibitively high surgical risks due to their age or comorbidities. MV repair devices under development address various components of the MV complex and generally are performed on the beating heart without the need for cardiopulmonary bypass. Approaches to MV repair include direct leaflet repair, repair of the mitral annulus via direct annuloplasty, or indirect repair based on the annulus's proximity to the coronary sinus. There are also devices in development to counteract ventricular remodeling, and systems designed for complete MV replacement via catheter.

Direct Leaflet Approximation

One device that undertakes direct leaflet repair, the MitraClip Clip Delivery System (Abbott Vascular), has been approved through the premarket approval process by the U.S. Food and Drug Administration (FDA) for use in certain patients with symptomatic primary MR. Of the transcatheter MV repair devices under investigation, MitraClip has the largest body of evidence evaluating its use; it has been in use in Europe since 2008. The MitraClip system is deployed percutaneously and approximates the open Alfieri edge-to-edge repair approach to treating MR. The delivery system consists of a catheter, a steerable sleeve, and the MitraClip device, which is a 4-mm wide clip fabricated from a cobalt-chromium alloy and polypropylene fabric. MitraClip is deployed via a transfemoral approach, with transseptal puncture used to access the left side of the heart and the MV. Placement of MitraClip leads to coapting of the mitral leaflets, thus creating a double-orifice valve.

The PASCAL (PAddles Spacer Clasps ALfieri) Mitral Repair System (Edwards Lifesciences) is also a direct coaptation device and works in a similar manner tothe MitraClip system. The delivery system consists of a 10-mm central spacer that attaches to the MV leaflets by 2 paddles and clasps (CE marked, which isa status of approval awarded by a quality organization in the European Union). Pivotal trials are ongoing in the United States.

Other MV Repair Devices

Devices for transcatheter MV repair that use various approaches are in development. Techniques to repair the mitral annulus include those that target the annulus itself (direct annuloplasty) and those that tighten the mitral annulus via manipulation of the adjacent coronary sinus (indirect annuloplasty). Indirect annuloplasty devices include the Carillon® Mitral Contour System™ (Cardiac Dimension) and the Monarc™ device

(Edwards Lifesciences). The CE-marked Carillon Mitral Contour System is comprised of self-expanding proximal and distal anchors connected with a nitinol bridge, with the proximal end coronary sinus ostium and the distal anchor in the great cardiac vein. The size of the connection is controlled by manual pullback on the catheter. The Carillon system was evaluated in the Carillon Mitral Annuloplasty Device European Union Study and the follow-up Tighten the Annulus Now study, with further studies planned. The Monarc system also involves 2 self-expanding stents connected by a nitinol bridge, with one end implanted in the coronary sinus via internal jugular vein and the other in the great cardiac vein. Several weeks after implantation, the biologically degradable coating over the nitinol bridge degrades, allowing the bridge to shrink and the system to shorten. It has been evaluated in the Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation trial.

Direct annuloplasty devices include the Mitralign Percutaneous Annuloplasty System (Mitralign) and the AccuCinch® System (Guided Delivery Systems), both of which involve transcatheter placement of anchors in the MV; they are cinched or connected to narrow the mitral annulus. Other transcutaneous direct annuloplasty devices under investigation include the enCorTC™ device (MiCardia), which involves a percutaneously insertable annuloplasty ring that is adjustable using radiofrequency energy, a variation on its CE-marked enCor$_{SQ}$ Mitral Valve Repair System, and the Cardioband Annuloplasty System (Valtech Cardio), an implantable annuloplasty band with a transfemoral venous delivery system.

Transcatheter MV Replacement
Permavalve (Micro Interventional Devices), under investigation in the U.S., is a transcatheter MV replacement device that is delivered via the transapical approach. On June 5, 2017, the SAPIEN 3 Transcatheter Heart Valve (Edwards Lifesciences) was approved by the FDA as a MV replacement device.

Medical Management
The standard treatment for patients with chronic secondary MR is medical management. Patients with chronic secondary MR should receive standard therapy for heart failure with reduced ejection fraction; standard management includes angiotensin converting enzyme inhibitor (or angiotensin II receptor blocker or angiotensin receptor-neprilysin inhibitor), b-blocker and mineralocorticoid receptor antagonist, and diuretic therapy as needed to treat volume overload. Resynchronization therapy may provide symptomatic relief, improve LV function, and in some patients, lessen the severity of MR. These replacement valves are outside the scope of this evidence review.

Regulatory Status
In October 2013, the MitraClip® Clip Delivery System (Abbott Vascular) was approved by the FDA through the premarket approval process for treatment of "significant symptomatic mitral regurgitation (MR ≥3+) due to primary abnormality of the mitral apparatus (degenerative MR) in patients who have been determined to be at a prohibitive risk for mitral valve surgery by a heart team."

In March 2019, the FDA approved a new indication for MitraClip, for "treatment of patients with normal mitral valves who develop heart failure symptoms and moderate-to-severe or severe mitral regurgitation because of diminished left heart function (commonly known as secondary or functional mitral regurgitation) despite being treated with optimal medical therapy. Optimal medical therapy includes combinations of different heart failure medications along with, in certain patients, cardiac resynchronization therapy and implantation of cardioverter defibrillators."

For individuals who have symptomatic primary MR and at prohibitive risk for open surgery who receive TMVR using MitraClip, the evidence includes a single-arm prospective cohort with historical cohort and registry studies. Relevant outcomes are overall survival (OS), morbid events, functional outcomes, and treatment-related morbidity. The primary evidence includes the pivotal EVEREST II HRR and EVEREST II REALISM studies and Transcatheter Valve Therapy Registry studies. These studies have demonstrated that MitraClip implantation is feasible with a procedural success rate greater than 90%, 30-day mortality ranging

from 2.3% to 6.4% (less than predicted Society of Thoracic Surgeons mortality risk score for MR repair or replacement; range, 9.5%-13.2%), postimplantation MR severity grade of 2+ or less in 82% to 93% of patients, and a clinically meaningful gain in quality of life (5- to 6-point gains in 36-Item Short-Form Health Survey scores). At 1 year, freedom from death and MR more than 2+ was achieved in 61% of patients but the 1-year mortality or heart failure hospitalization rates remain considerably high (38%). Conclusions related to the treatment effect on mortality based on historical controls cannot be made because the control groups did not provide unbiased or precise estimates of the natural history of patients eligible to receive MitraClip. Given that primary MR is a mechanical problem and there is no effective medical therapy, a randomized controlled trial (RCT) comparing MitraClip with medical management is not feasible or ethical. The postmarketing data from the U.S. is supportive that MitraClip surgery is being performed with short-term effectiveness and safety in a select patient population. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have heart failure and symptomatic secondary MR despite the use of maximally tolerated guideline-directed medical therapy who receive TMVR using MitraClip, the evidence includes a systematic review, 2 RCTs as well as multiple observational studies. Relevant outcomes are OS, morbid events, functional outcomes, and treatment-related morbidity. The trials had discrepant results potentially related to differences in primary outcomes. The larger trial, with patients selected for nonresponse to maximally tolerated therapy, found a significant benefit for MitraClip after 2 years compared to medical therapy alone. Improvements in MR severity, quality of life measures, and functional capacity persisted to 36 months in patients who received TMVR. The systematic review confirmed the benefit of MitraClip found in the larger RCT but had important methodological limitations. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have symptomatic primary or SMR and are surgical candidates who receive TMVR using MitraClip, the evidence includes a systematic review, 1 RCT, and a retrospective comparative observational study in individuals aged ≥ 75 years. Relevant outcomes are OS, morbid events, functional outcomes, and treatment-related morbidity. The RCT found that MitraClip did not reduce MR as often or as completely as the surgical control, although it could be safely implanted and was associated with fewer adverse events at 1 year. Long-term follow-up from the RCT showed that significantly more MitraClip patients required surgery for MV dysfunction than conventional surgery patients. For these reasons, this single trial is not definitive in demonstrating improved clinical outcomes with MitraClip compared with surgery. Additional RCTs are needed to corroborate these results. The observational study in individuals aged ≥ 75 years found that although MitraClip was associated with improved 1-year survival and a lower rate of all acute complications compared with surgical repair, it had lower 5-year survival and greater MR recurrence. The evidence is insufficient to determine s that the technology results in an improvement in the net health outcome.

For individuals who have symptomatic primary or secondary MR who receive TMVR using devices other than MitraClip, the evidence includes an RCT, nonrandomized prospective studies, and noncomparative feasibility studies. Relevant outcomes are OS, morbid events, functional outcomes, and treatment-related morbidity. A head-to-head RCT comparing the direct leaflet repair devices, PASCAL and MitraClip, is ongoing.Prospective nonrandomized trials demonstrate promising efficacy and safety results for the PASCAL direct leaflet repair device. A small open-label head-to-head comparison trial between PASCAL and MitraClip (Gercek et al 2021) demonstrated similar safety and efficacy between the 2 systems. Data from the ongoing RCT is needed to draw conclusions about the net health benefit. The randomized, sham-controlled trial for the indirect annuloplasty device Carillon® also offers promising safety data, however further studies are needed to determine efficacy and long-term outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

CODING

Medicare Advantage Plans

The following codes may be allowed as part of a CMS approved clinical study:

33418 Transcatheter mitral valve repair, percutaneous approach, including transseptal puncture when performed; initial prosthesis

33419 Transcatheter mitral valve repair, percutaneous approach, including transseptal puncture when performed; additional prosthesis(es) during same session (List separately in addition to code for primary procedure

0345T Transcatheter mitral valve repair percutaneous approach via the coronary sinus

Note: If you are treating a Medicare Advantage Plan member as part of a CMS approved study, please follow the procedures for correct billing and coding of services found in the policy for Clinical Trials for Medicare. Advantage Plans.

Claims for services rendered as part of a CMS approved clinical study must be billed with an appropriate modifier:

Modifier Q0 – Investigational clinical service provided in a clinical research study that is in an approved research study (Medicare claims filed without the Q0 modifier will deny as not medically necessary)

The following code requires prior authorization for Medicare Advantage Plans and follows the medical necessity criteria found in the Medical Necessity policy:

0544T Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transseptal puncture

Commercial Products

The following codes are considered medically necessary when the medical criteria above has been met:

33418 Transcatheter mitral valve repair, percutaneous approach, including transseptal puncture when performed; initial prosthesis

33419 Transcatheter mitral valve repair, percutaneous approach, including transseptal puncture when performed; additional prosthesis(es) during same session (List separately in addition to code for primary procedure

0345T Transcatheter mitral valve repair percutaneous approach via the coronary sinus

0544T Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transseptal puncture

RELATED POLICIES

Medicare Advantage Plans National and Local Coverage Determinations
Clinical Trials for Medicare Advantage Plans
Prior Authorization via Web-Based Tool for Procedures

PUBLISHED

Provider Update, November 2022
Provider Update, November 2021
Provider Update, December 2020
Provider Update, April 2020
Provider Update, September 2018

REFERENCES

1. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Transcatheter MITRAL Valve Repair (TMVR) (20.33). 2015; https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=363&ncdver=1&CoverageSelection=National&KeyWord=mitral&KeyWordLookUp=Title&KeyWordSearchType=And&bc=gAAAABAAAAAAAA%3d%3d&. Accessed March 16, 2022.

2. Chiam PT, Ruiz CE. Percutaneous transcatheter mitral valve repair: a classification of the technology. JACC Cardiovasc Interv. Jan 2011; 4(1): 1-13. PMID 21251623
3. Fedak PW, McCarthy PM, Bonow RO. Evolving concepts and technologies in mitral valve repair. Circulation. Feb 19 2008; 117(7): 963-74. PMID18285577
4. Carabello BA. The current therapy for mitral regurgitation. J Am Coll Cardiol. Jul 29 2008; 52(5): 319-26. PMID 18652937
5. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. Sep 23 2008; 52(13): e1-142. PMID18848134
6. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Feb 02 2021; 143(5): e72-e227. PMID 33332150
7. Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. Jan 21 2014; 63(2): 185-6. PMID 24036029
8. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. Jul 11 2017; 70(2): 252-289. PMID 28315732
9. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. Oct 2012; 33(19): 2451-96. PMID 22922415
10. Diodato MD, Moon MR, Pasque MK, et al. Repair of ischemic mitral regurgitation does not increase mortality or improve long-term survival in patients undergoing coronary artery revascularization: a propensity analysis. Ann Thorac Surg. Sep 2004; 78(3): 794-9; discussion 794-9. PMID 15336993
11. Wong DR, Agnihotri AK, Hung JW, et al. Long-term survival after surgical revascularization for moderate ischemic mitral regurgitation. Ann Thorac Surg. Aug 2005; 80(2): 570-7. PMID 16039207
12. Mihaljevic T, Lam BK, Rajeswaran J, et al. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol. Jun 05 2007; 49(22): 2191-201. PMID 17543639
13. Smith PK, Puskas JD, Ascheim DD, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. Dec 04 2014; 371(23): 2178-88. PMID 25405390
14. Young A, Feldman T. Percutaneous mitral valve repair. Curr Cardiol Rep. Jan 2014; 16(1): 443. PMID 24281977
15. Minha S, Torguson R, Waksman R. Overview of the 2013 Food and Drug Administration Circulatory System Devices Panel meeting on the MitraClip Delivery System. Circulation. Aug 20 2013; 128(8): 864-8. PMID 23960257
16. Noack T, Kiefer P, Besler C, et al. Transcatheter mitral valve repair: review of current techniques. Indian J Thorac Cardiovasc Surg. Jan 2020; 36(Suppl1): 53-63. PMID 33061185
17. Siminiak T, Wu JC, Haude M, et al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail. Aug 2012; 14(8): 931-8. PMID 22613584
18. Harnek J, Webb JG, Kuck KH, et al. Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation: 1-year results from the EVOLUTION phase I study (Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation). JACC Cardiovasc Interv. Jan 2011; 4(1): 115-22. PMID 21251638
19. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Mitral Valve Repair Device. 2013; https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100009b.pdf. Accessed March 16, 2022.

20. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Percutaneous mitral valve repair. TEC Assessments 2014; Volume 29:Tab 4.
21. Reichenspurner H, Schillinger W, Baldus S, et al. Clinical outcomes through 12 months in patients with degenerative mitral regurgitation treated with the MitraClip (R) device in the ACCESS-EUrope Phase I trial. Eur J Cardiothorac Surg. Oct 2013; 44(4): e280-8. PMID 23864216
22. Lim S, Kar S, Fail P, et al. The EVEREST II high surgical risk cohort: effectiveness of transcatheter reduction of significant mitral regurgitation in high surgical risk patients. J Am Coll Cardiol. 2013;61(10 Suppl):E1958.
23. Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol. Jul 15 2014; 64(2): 182-92. PMID 24184254
24. Ware J, Kosinski M, Bjorner JB, et al. User's Manual for the SF-36v2 Health Survey (2nd Ed). Lincoln, RI: QualityMetric; 2007.
25. Sorajja P, Mack M, Vemulapalli S, et al. Initial Experience With Commercial Transcatheter Mitral Valve Repair in the United States. J Am Coll Cardiol. Mar15 2016; 67(10): 1129-1140. PMID 26965532
26. Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes With Transcatheter Mitral Valve Repair in the United States: An STS/ACC TVT Registry Report. J Am Coll Cardiol. Nov 07 2017; 70(19): 2315-2327. PMID 29096801
27. Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol. Jul 15 2014; 64(2): 172-81. PMID 25011722
28. Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST(Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. Aug 18 2009; 54(8): 686-94. PMID 19679246
29. Chan PH, She HL, Alegria-Barrero E, et al. Real-world experience of MitraClip for treatment of severe mitral regurgitation. Circ J. 2012; 76(10): 2488-93. PMID 22785461
30. Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol. Jan 10 2012; 59(2): 130-9. PMID 22222076
31. Wan B, Rahnavardi M, Tian DH, et al. A meta-analysis of MitraClip system versus surgery for treatment of severe mitral regurgitation. Ann Cardiothorac Surg. Nov 2013; 2(6): 683-92. PMID 24349969
32. Bail DH, Doebler K. The MitraClip System: a systematic review of indications, procedural requirements, and guidelines. Thorac Cardiovasc Surg. Feb2014; 62(1): 18-25. PMID 24297637
33. Estevez-Loureiro R, Franzen O, Winter R, et al. Echocardiographic and clinical outcomes of central versus noncentral percutaneous edge-to-edge repair of degenerative mitral regurgitation. J Am Coll Cardiol. Dec 24 2013; 62(25): 2370-2377. PMID 24013059
34. Grasso C, Ohno Y, Attizzani GF, et al. Percutaneous mitral valve repair with the MitraClip system for severe mitral regurgitation in patients with surgical mitral valve repair failure. J Am Coll Cardiol. Mar 04 2014; 63(8): 836-8. PMID 24161329
35. Munkholm-Larsen S, Wan B, Tian DH, et al. A systematic review on the safety and efficacy of percutaneous edge-to-edge mitral valve repair with the MitraClip system for high surgical risk candidates. Heart. Mar 2014; 100(6): 473-8. PMID 23813844
36. Swaans MJ, Bakker AL, Alipour A, et al. Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients. JACC Cardiovasc Interv. Aug 2014; 7(8): 875-81. PMID 25147032
37. Philip F, Athappan G, Tuzcu EM, et al. MitraClip for severe symptomatic mitral regurgitation in patients at high surgical risk: a comprehensive systematic review. Catheter Cardiovasc Interv. Oct 01 2014; 84(4): 581-90. PMID 24905665
38. Vakil K, Roukoz H, Sarraf M, et al. Safety and efficacy of the MitraClip (R) system for severe mitral regurgitation: a systematic review. Catheter Cardiovasc Interv. Jul 01 2014; 84(1): 129-36. PMID 24323764

39. Bail DH. (Meta)-analysis of safety and efficacy following edge-to-edge mitral valve repair using the MitraClip system. J Interv Cardiol. Feb 2015; 28(1):69-75. PMID 25689550
40. Velazquez EJ, Samad Z, Al-Khalidi HR, et al. The MitraClip and survival in patients with mitral regurgitation at high risk for surgery: A propensity-matched comparison. Am Heart J. Nov 2015; 170(5): 1050-1059.e3. PMID 26542516
41. Hayashida K, Yasuda S, Matsumoto T, et al. AVJ-514 Trial - Baseline Characteristics and 30-Day Outcomes Following MitraClip (R) Treatment in a Japanese Cohort. Circ J. Jul 25 2017; 81(8): 1116-1122. PMID 28321004
42. Kumar A, Al-Khafaji J, Shariff M, et al. Percutaneous mitral valve repair for secondary mitral valve regurgitation: A systematic review and meta-analysis. Eur J Intern Med. Aug 2020; 78: 107-112. PMID 32094019
43. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. Dec 13 2018; 379(24): 2307-2318. PMID 30280640
44. Mack MJ, Lindenfeld J, Abraham WT, et al. 3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. J Am Coll Cardiol. Mar02 2021; 77(8): 1029-1040. PMID 33632476
45. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. Dec 132018; 379(24): 2297-2306. PMID 30145927
46. Iung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur J Heart Fail. Dec 2019; 21(12): 1619-1627. PMID 31476260
47. Atianzar K, Zhang M, Newhart Z, et al. Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip. Interv Cardiol. Feb 2019; 14(1): 45-47. PMID 30858892
48. Nishimura RA, Bonow RO. Percutaneous Repair of Secondary Mitral Regurgitation - A Tale of Two Trials. N Engl J Med. Dec 13 2018; 379(24): 2374-2376. PMID 30575469
49. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. Aug 2017; 23(8): 628-651. PMID 28461259
50. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. Sep 21 2017; 38(36):2739-2791. PMID 28886619
51. Takagi H, Ando T, Umemoto T. A review of comparative studies of MitraClip versus surgical repair for mitral regurgitation. Int J Cardiol. Feb 01 2017; 228:289-294. PMID 27865200
52. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. Apr 14 2011; 364(15): 1395-406. PMID21463154
53. Mauri L, Garg P, Massaro JM, et al. The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation. Am Heart J. Jul 2010; 160(1): 23-9. PMID 20598968
54. Mauri L, Foster E, Glower DD, et al. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol. Jul 23 2013; 62(4): 317-28. PMID 23665364
55. Feldman T, Kar S, Elmariah S, et al. Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVERESTII. J Am Coll Cardiol. Dec 29 2015; 66(25): 2844-2854. PMID 26718672
56. Buzzatti N, Van Hemelrijck M, Denti P, et al. Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: A propensity-weighted analysis. J Thorac Cardiovasc Surg. Jul 2019; 158(1): 86-94.e1. PMID 30797588
57. Lim DS, Kar S, Spargias K, et al. Transcatheter Valve Repair for Patients With Mitral Regurgitation: 30-Day Results of the CLASP Study. JACC Cardiovasc Interv. Jul 22 2019; 12(14): 1369-1378. PMID 31255562
58. Webb JG, Hensey M, Szerlip M, et al. 1-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study. JACC Cardiovasc Interv. Oct 26 2020; 13(20): 2344-2357. PMID 33092709

59. Szerlip M, Spargias KS, Makkar R, et al. 2-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study. JACC Cardiovasc Interv. Jul 26 2021; 14(14): 1538-1548. PMID 34020928
60. Gercek M, Roder F, Rudolph TK, et al. PASCAL mitral valve repair system versus MitraClip: comparison of transcatheter edge-to-edge strategies incomplex primary mitral regurgitation. Clin Res Cardiol. Dec 2021; 110(12): 1890-1899. PMID 33837469
61. Witte KK, Lipiecki J, Siminiak T, et al. The REDUCE FMR Trial: A Randomized Sham-Controlled Study of Percutaneous Mitral Annuloplasty in Functional Mitral Regurgitation. JACC Heart Fail. Nov 2019; 7(11): 945-955. PMID 31521683
62. Khan MS, Siddiqi TJ, Butler J, et al. Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to4+: results from the REDUCE-FMR trial. ESC Heart Fail. Apr 2021; 8(2): 872-878. PMID 33619896
63. Schofer J, Siminiak T, Haude M, et al. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation. Jul 28 2009; 120(4): 326-33. PMID 19597051
64. Bonow RO, O'Gara PT, Adams DH, et al. 2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. May 05 2020; 75(17): 2236-2270.PMID 32068084
65. O'Gara PT, Calhoon JH, Moon MR, et al. Transcatheter therapies for mitral regurgitation: a professional society overview from the American College of Cardiology, The American Association for Thoracic Surgery, Society for Cardiovascular Angiography and Interventions Foundation, and The Society of Thoracic Surgeons. J Thorac Cardiovasc Surg. Mar 2014; 147(3): 837-49. PMID 24529172
66. National Institute for Health and Care Excellence (NICE). Heart valve disease presenting in adults: investigation and management [NG208]. 2021;https://www.nice.org.uk/guidance/ng208/chapter/Recommendations. Accessed March 16, 2022.